ArticleCancer cell international2026
MicroRNA-29b-5p regulates cell proliferation and cancer stemness via TGF-β/p300 pathway in human synovial sarcoma.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Synovial sarcoma (SS) is a rare and aggressive soft tissue malignancy characterized by t(X;18)(p11.2;q11.2) translocation, which results in the SYT-SSX fusion gene. SS exhibits cancer stem cell-like properties that contribute to its invasiveness. Recent evidence implicates microRNA-29b (miR-29b) could regulate TGF-β pathway and its downstream gene EP300 may be involved in these traits. Bioinformatics tools (miRDB, TargetScan, and miRanda) were used to predict the interaction between miR-29b-5p and EP300, which was validated via dual-luciferase reporter assays and RNA-binding protein immunoprecipitation. The expression levels of miR-29b-5p and EP300, along with those of cancer stem cell markers, LIF-LIFR signaling, and Ki-67 proliferation indices, were analyzed in SS tissues, parental cells, and spheroid cells. Spheroids derived from SW982 and SSX1 cells cultured in serum-free suspension presented elevated levels of cancer stem cell markers and increased proliferation, migration, and invasion capacities, particularly SYT-SSX1-derived spheroids. Compared with parental cells, spheroids presented reduced miR-29b-5p expression and increased EP300 expression. The overexpression of miR-29b-5p suppressed spheroid formation; stemness marker expression; and cell proliferation, migration, and invasion, whereas its inhibition had the opposite effect. Compared with individual silencing, co-silencing of miR-29b-5p and EP300 further attenuated cancer stem cell-like traits, underscoring their regulatory interplay. In conclusion, miR-29b-5p may suppresses cancer stemness and aggressiveness in SS to some extent by targeting EP300, with a relatively more pronounced effect in SSX1 cells. Preliminarily these fundings suggest that miR-29b-5p-mediated modulation of EP300 and the TGF-β signaling pathway may provide a potential research data for synovial sarcoma studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.